These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20022572)

  • 21. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.
    Davidson MB; Thakkar S; Hix JK; Bhandarkar ND; Wong A; Schreiber MJ
    Am J Med; 2004 Apr; 116(8):546-54. PubMed ID: 15063817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.
    Campara M; Shord SS; Haaf CM
    J Clin Pharm Ther; 2009 Apr; 34(2):207-13. PubMed ID: 19250141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
    Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
    Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
    Herrington JD; Dinh BC
    J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
    Oldfield V; Perry CM
    Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
    De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
    Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
    Savva DA; Herrera N; Rohatgi R
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further studies on the use of allopurinol to reduce plasma uric acid concentrations in the Red-tailed Hawk (Buteo jamaicensis) hyperuricaemic model.
    Poffers J; Lumeij JT; Timmermans-Sprang EP; Redig PT
    Avian Pathol; 2002 Dec; 31(6):567-72. PubMed ID: 12593739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
    Coiffier B; Altman A; Pui CH; Younes A; Cairo MS
    J Clin Oncol; 2008 Jun; 26(16):2767-78. PubMed ID: 18509186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
    Cammalleri L; Malaguarnera M
    Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S; Lee CS; Ahn S; Sharma A
    J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rasburicase in the prevention and treatment of tumour lysis syndrome.
    Mayne N; Keady S; Thacker M
    Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.